Lataa...
New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
Dalbavancin, an intravenous glycopeptide, was approved by the US Food and Drug Administration in May 2014 for use in adult patients with acute bacterial skin and skin structure infections. The recommended dosing regimen for effective use of dalbavancin is 1,000 mg followed by a 500 mg dose after 1 w...
Tallennettuna:
| Julkaisussa: | Ther Clin Risk Manag |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4762434/ https://ncbi.nlm.nih.gov/pubmed/26937194 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S71855 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|